Legend Biotech Reports Advancement of Carvykti as 'Leading' Multiple Myeloma Treatment

MT Newswires Live12-10

Legend Biotech (LEGN) disclosed late Monday new results from a phase 3 study showing a single infusion of Carvykti provided "significantly higher" rates of minimal residual disease-negativity in patients with relapsed or lenalidomide-refractory multiple myeloma.

The medication is for patients who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent.

The company said that 89% of evaluable patients achieved minimal residual disease negativity with Carvykti after a three-year follow-up in the study, with the "majority in less than 2 months." The results "add" to the overall survival benefit recently reported.

"The latest MRD data showcases the advances of Carvykti and further demonstrates why it is a leading treatment for patients with multiple myeloma," said Ying Huang, chief executive officer of Legend Biotech.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490604320?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-10 18:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490604320","market":"hk","top_or_hot":-1,"title":"Legend Biotech Reports Advancement of Carvykti as 'Leading' Multiple Myeloma Treatment","media":"MT Newswires Live","content":"<html><body><p> Legend Biotech (LEGN) disclosed late Monday new results from a phase 3 study showing a single infusion of Carvykti provided \"significantly higher\" rates of minimal residual disease-negativity in patients with relapsed or lenalidomide-refractory multiple myeloma.</p><p>The medication is for patients who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent.</p><p>The company said that 89% of evaluable patients achieved minimal residual disease negativity with Carvykti after a three-year follow-up in the study, with the \"majority in less than 2 months.\" The results \"add\" to the overall survival benefit recently reported.</p><p>\"The latest MRD data showcases the advances of Carvykti and further demonstrates why it is a leading treatment for patients with multiple myeloma,\" said Ying Huang, chief executive officer of Legend Biotech.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Legend Biotech Reports Advancement of Carvykti as 'Leading' Multiple Myeloma Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLegend Biotech Reports Advancement of Carvykti as 'Leading' Multiple Myeloma Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-10 18:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Legend Biotech (LEGN) disclosed late Monday new results from a phase 3 study showing a single infusion of Carvykti provided \"significantly higher\" rates of minimal residual disease-negativity in ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2490604320","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490604320","pubTimestamp":1733825829,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Legend Biotech  disclosed late Monday new results from a phase 3 study showing a single infusion of Carvykti provided \"significantly higher\" rates of minimal residual disease-negativity in patients with relapsed or lenalidomide-refractory multiple myeloma.The medication is for patients who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent.The company said that 89% of evaluable patients achieved minimal residual disease negativity with Carvykti after a three-year follow-up in the study, with the \"majority in less than 2 months.\" The results \"add\" to the overall survival benefit recently reported.\"The latest MRD data showcases the advances of Carvykti and further demonstrates why it is a leading treatment for patients with multiple myeloma,\" said Ying Huang, chief executive officer of Legend Biotech.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4505":"高瓴资本持仓","BK4139":"生物科技","LEGN":"传奇生物","BK4588":"碎股"},"translate_title":"传奇生物报告Carvykti作为“领先”多发性骨髓瘤治疗方法的进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LEGN":1},"content_text":"Legend Biotech (LEGN) disclosed late Monday new results from a phase 3 study showing a single infusion of Carvykti provided \"significantly higher\" rates of minimal residual disease-negativity in patients with relapsed or lenalidomide-refractory multiple myeloma.The medication is for patients who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent.The company said that 89% of evaluable patients achieved minimal residual disease negativity with Carvykti after a three-year follow-up in the study, with the \"majority in less than 2 months.\" The results \"add\" to the overall survival benefit recently reported.\"The latest MRD data showcases the advances of Carvykti and further demonstrates why it is a leading treatment for patients with multiple myeloma,\" said Ying Huang, chief executive officer of Legend Biotech.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490604320"}